» Articles » PMID: 35059476

Cancellous Bone-like Tissue Replacement from Calcinosis in Patients with Systemic Sclerosis with Multiple External Root Resorption

Overview
Journal Bone Rep
Date 2022 Jan 21
PMID 35059476
Authors
Affiliations
Soon will be listed here.
Abstract

Calcinosis is frequently observed in patients with systemic sclerosis (SSc). The fundamental treatment of calcinosis has not yet been established. During follow-up, calcinosis in the subcutaneous surface is often spontaneously extracted or remains confined by fibrous tissues. We previously identified a new symptom in SSc patients, multiple external root resorption (MERR), and these patients had calcifications in the nasal spine. Here, we report for the first time that calcinosis at the nasal spine in patients with MERR can be replaced by cancellous bone-like tissue. Patients 1 and 2 were a 62-year-old Japanese female and a 45-year-old Japanese female (respectively) with MERR who had been previously treated for SSc (Patient 1: limited type, positive for anti-centromere antibody; Patient 2: diffuse type, positive for anti-Scl70 and anti-SS-A antibodies). Patient 3 was a 57-year-old female with MERR who had been previously treated for SSc (diffuse type, positive anti-Scl-70 antibody) and underwent denosumab injection for osteoporosis. Cone-beam computed tomography (CBCT) and CT images in the calcifications at the nasal spine in Patient 1 and 2 were replaced with cancellous bone-like tissue, but not in Patient 3. Serum laboratory examination was performed to assess the systemic bone disease. All three patients had normal clinical data within the references, apart from slightly higher 1,25-dihydroxyvitamin D levels in Patient 1. SSc patients with calcinosis in the maxillofacial area need to be examined carefully for bone replacement using CBCT or CT.

References
1.
Burgess K, Herrick A, Watson R . Systemic sclerosis skin is a primed microenvironment for soft tissue calcification-a hypothesis. Rheumatology (Oxford). 2021; 60(6):2517-2527. DOI: 10.1093/rheumatology/keab156. View

2.
Yolcu Y, Wahood W, Goyal A, Alvi M, Reeves R, Qu W . Pharmacologic prophylaxis for heterotopic ossification following spinal cord injury: A systematic review and meta-analysi. Clin Neurol Neurosurg. 2020; 193:105737. DOI: 10.1016/j.clineuro.2020.105737. View

3.
Jin W, Lin X, Pan H, Zhao C, Qiu P, Zhao R . Engineered osteoclasts as living treatment materials for heterotopic ossification therapy. Nat Commun. 2021; 12(1):6327. PMC: 8566554. DOI: 10.1038/s41467-021-26593-1. View

4.
Botzoris V, Argyropoulou M, Voulgari P, Zikou A, Drosos A . Heterotopic ossification in systemic sclerosis. Scand J Rheumatol. 2009; 38(4):317-9. DOI: 10.1080/03009740902776919. View

5.
Pignolo R, Ramaswamy G, Fong J, Shore E, Kaplan F . Progressive osseous heteroplasia: diagnosis, treatment, and prognosis. Appl Clin Genet. 2015; 8:37-48. PMC: 4321643. DOI: 10.2147/TACG.S51064. View